FDA Expands Approval for Jylamvo to Children With Acute Lymphoblastic Leukemia
Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases.
Syncona : Autolus Receives FDA Approval For AUCATZYL In Adults With Relapsed/Refractory B-ALL
Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has
Aucatzyl Approved for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults.
Autolus Therapeutics Gets FDA Approval for Cancer Treatment
Autolus Therapeutics said it received Food and Drug Administration approval of its treatment of acute lymphoblastic leukemia, or ALL, an aggressive blood and bone marrow cancer, for certain patients.
Autolus Therapeutics announces FDA approval of Aucatzyl
Autolus Therapeutics (AUTL) announces the U.S. FDA has granted marketing approval for Aucatzyl for the treatment of adult patients with
Autolus wins FDA approval of Aucatzyl for acute lymphoblastic leukemia
The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Mum claims GP said her four-year-old was ‘faking it’ week before leukaemia diagnosis
Mum claims GP said her four-year-old was ‘faking it’ week before leukaemia diagnosis - Summer’s mum is warning other parents to ‘trust their instinct’ ...
The American Journal of Managed Care4d
Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia
A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation. Adding blinatumomab to consolidation chemotherapy ...
Cancer Therapy Advisor14h
FDA Approves Obecabtagene Autoleucel for Adults With BCP-ALL
The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Cure Today3d
FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
The American Journal of Managed Care3d
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...
Targeted Oncology7d
Optimizing Transplant Timing in Acute Lymphoblastic Leukemia
Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
Daily Herald8d
From great loss, a promise: Son’s death inspires Barrington couple’s foundation
Nearly 25 years ago, Ann and Jim Pride endured the unimaginable when their son Jeff — a happy boy who liked the color blue ...